Key result
RISE protocol aims to validate the simplified Geneva score and accelerometry for predicting hospital-acquired VTE.
Why the study?
The simplified Geneva score for hospital-acquired VTE risk assessment lacks prospective validation, and immobility definitions in existing risk assessment models are inconsistent and subjective.
Does the simplified Geneva score and objective accelerometry-based mobility measurement accurately predict hospital-acquired VTE at 90 days in medically ill inpatients?
Cohort (n=1,350)
Yes
Does the simplified Geneva score and objective accelerometry-based mobility measurement accurately predict hospital-acquired VTE at 90 days in medically ill inpatients?
This study protocol outlines a prospective cohort study to validate the simplified Geneva score and objective accelerometry for predicting hospital-acquired VTE in medical inpatients.
Should not yet change VTE risk assessment in medical inpatients; leaves open whether simplified Geneva score or accelerometry improves 90-day prediction.
Background Hospital-acquired venous thromboembolism (VTE) is one of the leading preventable causes of in-hospital mortality. However, its risk assessment in medically ill inpatients is complicated due to the patients’ heterogeneity and complexity of currently available risk assessment models (RAMs). The simplified Geneva score provides simplicity but has not yet been prospectively validated. Immobility is an important predictor for VTE in RAMs, but its definition is inconsistent and based on subjective assessment by nurses or physicians. In this study, we aim to prospectively validate the simplified Geneva score and to examine the predictive performance of a novel and objective definition of in-hospital immobilization using accelerometry. Methods and analysis RISE is a multicenter prospective cohort study. The goal is to recruit 1350 adult inpatients admitted for medical illness in three Swiss tertiary care hospitals. We collect data on demographics, comorbidities, VTE risk and thromboprophylaxis. Mobility from admission to discharge is objectively measured using a wrist-worn accelerometer. Participants are followed for 90 days for the occurrence of symptomatic VTE (primary outcome). Secondary outcomes are the occurrence of clinically relevant bleeding, and mortality. The evolution of autonomy in the activities of daily living, the length of stay, and the occurrence of readmission are also recorded. Time-dependent area under the curve, sensitivity, specificity, and positive and negative predictive values are calculated for each RAM (i.e. the simplified and original Geneva score, Padua, and IMPROVE score) with and without the objective mobility measures to assess their accuracy in predicting hospital-acquired VTE at 90 days. Ethics and expected impact The ethics committee approved the protocol and the study was registered on ClinicalTrials.gov as NCT04439383 . RISE has the potential to optimize VTE risk stratification, and thus to improve the quality of care of medically hospitalized patients.
No takes yet. Share an insight, caveat, or question.
Choffat et al. (2022) conducted a cohort in Hospital-acquired venous thromboembolism (VTE) (n=1,350). Simplified Geneva score and accelerometry-assessed mobility vs. Original Geneva, Padua, and IMPROVE scores; subjective mobility assessment was evaluated on Symptomatic objectively confirmed fatal and non-fatal VTE up to 90 days after hospital admission. The RISE prospective cohort study protocol outlines a plan to validate the simplified Geneva score and evaluate accelerometry-based mobility assessment for predicting hospital-acquired VTE in 1350 medical inpatients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: